lonafarnib has been researched along with Carcinoma, Anaplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Béliveau, R; Cusson, MH; Desrosiers, RR; Turcotte, S | 1 |
| Adjei, AA; Bruzek, LM; Kaufmann, SH; Poynter, JN | 1 |
2 other study(ies) available for lonafarnib and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.
Topics: Alkyl and Aryl Transferases; Carcinoma; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Culture Media; Dose-Response Relationship, Drug; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Farnesyltranstransferase; Fibrinolysin; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Kinetics; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Piperidines; Plasminogen; Protein Isoforms; Proto-Oncogene Proteins p21(ras); Pyridines; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator | 2005 |
Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamid
Topics: Alkyl and Aryl Transferases; Carcinoma; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; HCT116 Cells; Humans; Piperidines; Pyridines | 2005 |